Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

September 2024

Efficacy and safety of intravenous secukinumab for the treatment of active psoriatic arthritis: Results from the randomized, placebo-controlled Phase III INVIGORATE-2 study

Arthritis Rheumatol 2024 doi: 10.1002/art.42997

Kotha R,

Zhu X,

IV secukinumab provided rapid and sustained improvements in disease signs and symptoms at Week 16 and through 52 weeks. Kivitz et al. evaluated the long-term efficacy, safety, and tolerability of IV secukinumab in patients with active PsA.

Keywords:

Secukinumab in Enthesitis-related Arthritis and Juvenile Psoriatic Arthritis: A Randomised, Double-blind, Placebo-controlled, Treatment Withdrawal, Phase 3 Trial

Ann Rheum Dis. 2022 2022 2022-222849

Ayaz NA,

Ozen S,

Scott C,

Zhu X,

Ruperto N; Paediatric Rheumatology INternational Trials Organization (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG)

In the latest study by Brunner, et al. secukinumab demonstrated efficacy and safety in the JIA categories of ERA and JPsA. This phase 3 study aimed to demonstrate the efficacy and safety of secukinumab in patients with active ERA and JPsA.